Following activation by its cognate ligand(s), the epidermal growth factor receptor (EGFR) is rapidly routed to the lysosome for degradation in a ubiquitination-dependent fashion. This pathway represents the major mechanism of long-term attenuation of EGFR signaling, and its deregulation is a significant feature in different types of cancers. Here we demonstrate, through a systematic RNAi-based approach, that several deubiquitinating (DUB) enzymes extend or decrease EGFR half-life upon EGF stimulation. We focus on USP9X, whose depletion severely affects EGFR turnover, interfering with its internalization and trafficking. We identify the endocytic protein Eps15 as one of the critical substrates of USP9X, and we map the Eps15 ubiquitination sites. We found that Eps15 monoubiquitination occurs already at minimal dose of EGF stimulation and is essential for EGFR internalization. Overall, our findings identify USP9X as a novel regulator of EGFR endocytosis and suggest a model whereby cycles of ubiquitination and deubiquitination events on endocytic accessory proteins may regulate the internalization and trafficking of the EGFR toward the lysosomes.
In Brief
Savio et al. undertook a siRNA screen to find 18 DUBs that affect EGFR degradation. They focus on USP9X, whose depletion significantly delayed EGFR internalization and trafficking. USP9X counteracts monoubiquitination of Eps15 that occurs at minimal EGF dose and is critical for EGFR internalization.
INTRODUCTION
Deregulated epidermal growth factor receptor (EGFR) signaling is a significant feature in different stages of oncogenesis and in several types of cancer, e.g., ovarian cancer, lung cancer, and glioblastoma [1] [2] [3] . Uncontrolled EGFR signaling has been ascribed to overexpression of the receptor or of its ligand(s), activating mutations in the EGFR kinase domain, deregulation of key signaling components downstream of the receptor, and escaping down-modulation and degradation of the receptor [4] [5] [6] [7] . Conjugation of ubiquitin to the EGFR mediated by the E3 ligase Cbl [8] commits the receptor to lysosomal degradation and is the major mechanism by which long-term signal attenuation is achieved [9, 10] . As such, lack of EGFR ubiquitination is one of the options adopted by cancer cells to escape signal attenuation [6] .
Ubiquitination of the EGFR is dispensable for its clathrin-mediated internalization (CME) [11, 12] but is required for the activation of its non-clathrin endocytosis (NCE) [13, 14] . Indeed, under conditions of high receptor activation (as obtained, for instance, by high doses of EGF), the activation of NCE protects cells from overstimulation and commits the majority of the EGFR to lysosomal degradation [15] .
The ubiquitination status of the EGFR is the result of a balance between the activities of E3 ubiquitin ligases and deubiquitinating enzymes (DUBs). Thus, DUBs represent an additional step in the regulation of EGFR signaling [16, 17] . DUBs may counteract EGFR ubiquitination at three different levels in the endocytic process: (1) internalization, where ubiquitination plays a critical role in the choice of entry route; (2) endosomal sorting, where the ubiquitinated receptor is trafficked to the lysosomes for degradation, while the unmodified receptor is recycled back to the plasma membrane; and (3) multivesicular body (MVB) station, where deubiquitination of cargos en route to lysosomal degradation is required to maintain the free ubiquitin pool.
DUB activity may impinge on EGFR fate either directly, acting toward the receptor itself, or indirectly by regulating the ubiquitination status of the endocytic machinery. Indeed, adaptor proteins required for internalization (e.g., Eps15, Eps15R, and epsin) and sorting (e.g., Hrs and STAM) undergo EGF-induced monoubiquitination [18] [19] [20] [21] through a coupled monoubiquitination mechanism [22] . It has been proposed that this mechanism represents a signal to ''switch off'' the binding activity of the endocytic proteins by allowing intramolecular interactions between the UBD (ubiquitin-binding domain) and the Ub moiety present in cis [23] . The DUB that may counteract this process remains yet to be discovered. Moreover, possible modulation of Eps15 monoubiquitination by EGF dose was not evaluated.
Up to date, five DUBs have been described that are, either directly or indirectly, involved in EGFR endocytosis. The best characterized is AMSH (associated molecule with the SH3 domain of STAM), whose knockdown leads to enhanced degradation of the receptor [24, 25] . More recently, OTUD7/Cezanne-1 [26] and USP2 [27] were shown to prevent EGFR degradation by opposing receptor ubiquitination and causing enhanced EGFR signaling. UBPY/USP8, instead, affects the rate of EGFR degradation indirectly by regulating the turnover of the ESCRT (endosomal sorting complexes required for transport)-0 complex proteins Hrs and STAM [28, 29] . Finally, USP18 affects the EGFR pathway by acting at the level of protein translation [30, 31] . It is noteworthy that the magnitude of the effect on EGFR degradation, exerted by the depletion of the mentioned DUBs, is somehow limited. This, in turn, suggests the existence of additional, yet unidentified DUBs that are able to regulate EGFR endocytosis and/or degradation.
Herein, we describe a genome-wide siRNA screening, targeting 92 active DUBs, aimed to elucidate the entire repertoire of DUBs involved in the regulation of EGFR degradation. We show that several DUBs affect the EGFR pathway, and we investigate the molecular mechanisms through which USP9X severely affects EGFR internalization and degradation.
RESULTS
A Genome-wide siRNA Screen Identifies DUBs that Control EGFR Turnover To identify DUBs that regulate EGFR endocytosis, a siRNA library, targeting 92 active DUBs and composed of a pool of two oligos for each targeted gene, was designed and synthesized (Table S1 ; see also Experimental Procedures). HeLa cells were transiently transfected with these pools and stimulated with 100 ng/ml of EGF. EGFR degradation kinetics were then determined by two approaches: (1) immunoblot analysis and (2) ELISA-based assay called DELFIA (dissociationenhanced lanthanide fluoroimmunoassay) [13] (Figures 1A,  S1A , and S1B). The correlation between the two approaches was determined by establishing, for each DUB, the slope of the degradation rate with the two methods ( Figure S1C ). 76% of the analyzed DUBs showed a correlation higher than 0.9, demonstrating a good concordance between the two assays (Figure S1D) . A scatterplot that ranks the DUBs according to their rate of EGFR degradation by immunoblot (x axis) or DELFIA (y axis) is shown Figure 1B . We observed three main phenotypes upon DUBs knockdown (KD): (1) a degradation rate similar to control cells (i.e., cells knocked down with scramble oligos); (2) a faster degradation rate (e.g., USP25 and BRCC36; Figure 1C) ; and (3) a slower degradation rate (e.g., USP9X and USP10; Figure 1D ) in comparison to control cells.
Of note, the relative variation in EGFR degradation kinetics upon knockdown of AMSH, USP8, USP2, and OTUD7B reflects previously published data [25] [26] [27] 29] , supporting the reliability of our screen. Limited to the USP family, we also tested additional pa- rameters, including MAPK, AKT, and Hrs phosphorylation kinetics by immunoblot. The results summarized in Table S2 represent a resource depicting the impact of the DUBs KD on various signaling pathways. We proceeded with validation of the DUBs that displayed major alterations in EGFR degradation kinetics (24 DUBs; Figure 1B, shown in circles). In this panel, we included the previously characterized USP2 and OTUD7B as positive controls [26, 27] . The two oligos of the initial oligo pools were individually tested for each of the selected 24 DUBs, and the knockdown efficiency was assessed by qRT-PCR (Table S3). In 15 out of 24 cases (including USP2 and OTUD7B), the two individual oligos showed congruent phenotypes among themselves and with the oligo pool (Figure S2A) . In six cases, the interpretation of the results was hampered by the limited knockdown (and phenotype) obtained with individual oligos or by discrepancies between the phenotypes observed with the two individual oligos (i.e., USP32; Figure S2B ). Additional studies will be needed to resolve these cases. Only in three cases, we observed clear phenotypes in the absence of mRNA depletion, suggestive of an offtarget effect ( Figure S2C ; Table S3 ).
Taken together, these data show that we have identified 13 DUBs with a previously unsuspected impact on EGFR degradation kinetics.
Knockdown of USP9X Impacts on EGFR Fate
One of the strongest effects on EGFR turnover was exerted by the knockdown of USP9X (Figure 2A ). Indeed, depletion of USP9X caused a significant delay in EGFR degradation, leaving 80% of the initial EGFR intact even 2 hr post-stimulation, as shown by both IB and DELFIA analyses ( Figures 2B and 2C ).
Altered EGFR degradation phenotype may be caused by a change in the internalization and/or in the trafficking of the EGFR. To gain additional information, we assessed the phosphorylation status of different signaling and adaptor proteins acting downstream activated EGFR. We tested MAPK and AKT as downstream effectors of the signaling cascade and Hrs phosphorylation as a readout of EGFR trafficking. Whereas the kinetic of AKT phosphorylation was not significantly altered, the phosphorylation peaks of MAPK and of Hrs were reduced upon USP9X depletion ( Figure 2A ). The rapidity of Hrs phosphorylation/dephosphorylation directly correlates with EGFR degradation [32, 33] , suggesting that, in the absence of USP9X, trafficking of the EGFR might be altered.
To evaluate a possible role exerted by this DUB on EGFR internalization, we performed quantitative internalization assays with 125 I-EGF. We tested different EGF doses, because we have previously shown that EGFR ubiquitination by the E3 ligase Cbl is sharply activated after a certain threshold of EGF concentration [13] . In USP9X-depleted cells, the internalization rate (K e ) of the EGFR was reduced 2-fold compared to control cells under conditions of both low and high doses of EGF ( Figures 2D and 2E ), favoring the idea that USP9X acts already at the level of EGFR internalization. The observation was confirmed in stable knockdown clones of USP9X (USP9X-KD; Figure S3 ). To exclude a general defect in CME upon USP9X depletion, we assessed the internalization of two membrane receptors that utilize the same pathway, TfR and LDLR, which showed no alteration ( Figure S4A ).
Next, we sought to visualize the effects of USP9X depletion on EGFR trafficking at the single cell level using an anti-EGFR antibody (13A9) that recognizes the extracellular part of the EGFR without interfering with ligand binding or internalization [34] . As a positive control, we used USP8 depletion, which has previously been shown to affect EGFR trafficking [29] . In accordance with the slower internalization kinetics upon USP9X knockdown, EGF-EGFR colocalization signal could be observed at the plasma membrane at 3 min after stimulation in USP9X-KD, whereas in control cells, the signal was mainly in the endosomal compartment at the same time point (Figure 3 ). Two hours poststimulation, the EGFR was no longer visible in control cells, whereas in USP9X-KD cells, similar to cells depleted of USP8 [29] , a major fraction of the EGFR was still present in intracellular compartments ( Figure 3 ).
Trafficking of EGFR Is Delayed upon USP9X Knockdown
The above data showed that, in addition to an internalization defect, USP9X-depleted cells displayed accumulation of EGFR in endosomes under conditions of EGF stimulation. This prompted us to investigate EGFR trafficking in detail in USP9X-KD cell line ( Figure S3 ). Antibodies against EEA1 (early endosomes) and LAMP1 (late endosomes/lysosomes) were used to track the trafficking of internalized EGF ( Figures S4B and S4C ). At variance with control cells, a fraction of the internalized ligand still colocalized with EEA1 at 60 and 120 min post-stimulation in USP9X knockdown cells ( Figure S4B ). Concomitantly, we scored a reduction in the localization of EGFR at the late endosomal/lysosomal compartments marked by Lamp1 staining, compared to control cells ( Figure S4C ).
To exclude that the delayed trafficking was simply the consequence of the initial defect in internalization, we set up a trafficking assay (see Supplemental Experimental Procedures for details), where we followed the fate of the internalized EGFR. In this assay, internalization was performed for 45 min at 16 C, a condition that allows internalization but prevents subsequent steps, namely endosome recycling or maturation [35, 36] . Cells were then shifted at 37 C and fixed after different time points. Even under these conditions, in which the internalization defect was compensated for, the trafficking defect was clearly visible ( Figure 4A ). Total EGF intensity ( Figure 4B ) as well as number of EGF vesicles/cell ( Figure 4C ) were decreased over the time in control cells, attesting for EGFR degradation. This kinetic is delayed in USP9X-KD cells. The sum of these results indicates that the lack of USP9X causes two independent phenotypes on the EGFR endocytic pathway: an internalization defect and a general delay in the kinetics of EGFR trafficking to the lysosomes. Notably, rescue experiments performed with wild-type or catalytically inactive USP9X C1566S (C/S) mutant ( Figure S5 ) demonstrated that both phenotypes are caused by the lack of USP9X enzymatic activity.
Ubiquitination of Endocytic Adaptor Proteins Is Increased upon USP9X Knockdown
We then assessed the possible substrates of USP9X deubiquitinating activity. One obvious target is the EGFR itself. We thus examined the ubiquitination status of the receptor by immunoprecipitating endogenous EGFR at different time points from HeLa control and USP9X-KD cells stimulated with 100 ng/ml of EGF ( Figure 5A ). No significant variation was evident when the data were normalized for the total amount of EGFR ( Figure S6A ) or by DELFIA analysis ( Figure S6B) .
It has been shown that USP9X regulates different downstream effectors/adaptors involved in endocytosis, including the E3 ligase ITCH [37] and the TGFb mediator Smad4 [38] . This raises the possibility that the effects of USP9X on EGFR internalization/ trafficking are due to regulation of the ubiquitination state of endocytic accessory proteins. To gain insight into this issue, we first analyzed, with an unbiased approach, possible changes in the ubiquitination status of the proteome upon EGF stimulation using FK-2 immunoprecipitation coupled with quantitative proteomics (SILAC [stable isotope labeling with amino acids in cell culture]) [39] , a method that we have previously validated [40] . An example of sample preparation is shown in Figures S6C-S6E . Three independent experiments yielded good overlapping results (Table S4) . Using this approach, we further confirmed that EGFR ubiquitination is not increased in the absence of USP9X. Among the most-promising candidates, we found Eps15 and epsin1 (Table S4) , well-known adaptors involved in EGFR endocytosis [14] . We validated them by looking at their post-translational and protein level changes in immunoblot analysis ( Figure 5B ). Increased levels of modified Eps15 (indicated by arrowheads in Figure 5B ) were evident upon depletion of USP9X. The same behavior, though to a lesser extent, is visible for epsin1 and 2 ( Figure 5B) . No appreciable changes, compared to control cells, were detectable in Cbl and Nedd4 protein levels, the two main E3 ligases involved in the EGFR internalization pathway [8, 22, 41] . Immunoprecipitation experiments performed with either anti-Eps15-or antiepsin1/2-specific antibodies, followed by anti-Ub IB, showed increased ubiquitination of these proteins upon USP9X silencing and 100 ng/ml EGF stimulation ( Figures 5C and 5D ). Reciprocal IP/IB experiments further confirmed these results ( Figure 5E ).
We further analyzed Eps15 as the most-promising USP9X substrate. By coIP experiments, we obtained evidence of a physical interaction between USP9X and Eps15 in vivo (Figure 5F ). Using an in vitro DUB assay, we demonstrated that catalytic domain of USP9X wild-type, but not its inactive mutant (C/S), has the ability to deubiquitinate Eps15 immunoprecipitated from cells stimulated with 100 ng/ml of EGF ( Figure 5G) .
Together, these data show that Eps15 is a direct target of USP9X.
USP9X and Eps15/Epsins KD Have No Additive Effect on EGFR Internalization
We have previously shown that Eps15, Eps15R (Eps15-related protein), and epsin are redundantly involved in EGFR trafficking. Although individual silencing of these proteins has a minor effect [14, 42] , the triple Eps15/Eps15R/epsin1 knockdown (henceforth triple-KD) exhibits a significant decrease in EGFR internalization at low EGF dose [14] . To assess whether the action of USP9X on EGFR internalization impinges on these proteins, we knocked down USP9X in control cells and in the triple-KD cells ( Figure 6A ). USP9X knockdown reduced the internalization rate of the EGFR, as described above, whereas it did not further decrease the internalization rate in the triple-KD cells ( Figure 6A ). The lack of additive effects of the triple-KD and of the USPX9-KD suggests that the impact of USP9X on EGFR internalization requires the presence of Eps15/R and epsin1, even though alternative explanations could still be possible.
Characterization of an Eps15 Ubiquitination-Impaired Mutant
Prompted by these results, we further investigated the functional role of Eps15 monoubiquitination [20] . First, we undertook a mass spectrometry approach aimed at identifying the site(s) of ubiquitination on Eps15 upon EGF stimulation (100 ng/ml; see Experimental Procedures for details). We identified two major sites (K802 and K820) and two minor sites (K818 and K837), all located in the C terminus of the protein (Figures 6B and S7A) . Thus, we generated monoubiquitination mutants of Eps15, by mutagenizing the relevant lysines into arginines, and tested their ubiquitination in vivo. The tested mutants were Eps15 2KR (802 and 820), Eps15 4KR (802, 818, 820, and 837), and Eps15 6KR (802, 818, 820, 837, 861, and 891). In this latter mutant, we also mutagenized two lysine residues that were not detected in the mass spectrometry analysis but reside in the same terminal region as often ubiquitin-accepting residues work in a redundant fashion. The mutants were stably transfected into mouse embryonic fibroblasts knockout cells for Eps15 [43] , to avoid confounding effects due to the presence of the endogenous protein (e.g., dimerization) [44] . As also Ep15 tyrosine phosphorylation occurs upon EGF stimulation [45] , we evaluated the behavior of the mutants related to both post-translational modifications. As shown in Figure S7B , whereas phosphorylation status of all mutants was comparable to that of the wild-type protein, there was a gradient of ubiquitination in the mutants, with Eps15 6KR mutant showing the clearest impairment in monoubiquitination upon EGF stimulation. As a phospho-impaired mutant showed unaltered ubiquitination ( Figure S7C ), we concluded that the two post-translational modifications of Eps15 are regulated independently.
We then validated the 6KR as monoubiquitination-impaired mutant in HeLa cells, in which all our analyses have been performed. HeLa Eps15/Eps15R knockdown cells were stably transfected with HA-tagged wild-type or 6KR mutant. Expression levels of both proteins were similar to those of the endogenous protein ( Figure S7D ). In this cellular context, we confirmed that the monoubiquitination of the 6KR mutant is impaired, whereas its phosphorylation is intact ( Figure 6B) . Importantly, the 6KR mutant was still able to bind to free Ub ( Figure S7E ) or activated EGFR (Figure S7F ), confirming that Eps15 recruitment to the EGFR requires the Ub-binding ability of its ubiquitin-interacting motif (UIM), whereas Eps15 monoubiquitination is dispensable [14, 22] .
Monoubiquitination of Eps15 Occurs Already at Limiting Dose Stimulation and Is Required for EGFR Internalization
The experiments shown in Figures 2D and 6A suggest that USP9X activity is critical for EGFR internalization already at low EGF concentration when only the clathrin-mediated pathway is operative [15] . We have previously shown minimal EGFR ubiquitination at low dose [13, 15] . Possible modulation of Eps15 monoubiquitination by EGF dose was not evaluated. Thus, we examined Eps15 and EGFR ubiquitination at low (1.5 ng/ml) and high EGF (100 ng/ml) concentration. As visible in Figure 6C , the two proteins have distinct ubiquitination profiles. Whereas massive EGFR ubiquitination occurs only at high dose of EGF [13, 15] , Eps15 monoubiquitination is not influenced by the amount of EGF used to stimulate the cells and occurs already upon minimal activation of the EGFR.
Next, we assessed the impact of the 6KR mutant on EGFR internalization. To obtain the depletion of all the relevant proteins [13, 14] , we transiently knocked down epsin1 in Eps15/Eps15R double knockdown and we measured a defect in the EGFR internalization at low EGF concentration ( Figure 6D ) comparable to that of the triple-KD ( Figure 6A) . Importantly, the expression of the Eps156KR mutant was unable to rescue this phenotype, at variance with wild-type Eps15 ( Figure 6D ). This result argues that Eps15 monoubiquitination is a positive requirement for EGFR CME.
Impaired Eps15 Monoubiquitination Affects Eps15-EGFR Co-trafficking
Previous data based on artificial chimeras have suggested that, once ubiquitinated, endocytic adaptor proteins are kept in a close conformation to prevent interaction with their cargos [23, 46] . To obtain physiologically relevant information, we analyze the behavior of the endogenous Eps15 upon 100 ng/ml EGF stimulation. Monoubiquitinated Eps15 co-eluted with unmodified Eps15 in gel filtration analysis ( Figure 7A ) and was able to interact with activated EGFR [14] or with AP-2 indistinguishable from unmodified Eps15 (Figures 7B and 7C) . Thus, we concluded that monoubiquitination does not trigger release of Eps15 from the cargos.
To assess the possible role of monoubiquitination in the EGFR pathway, we followed the localization of Eps15 upon EGF stimulation, taking advantage of our HeLa cells stably transfected with HA-tagged Eps15 wild-type or 6KR mutant. In agreement with our previous finding [45] , Eps15 wild-type was able to relocalize at the plasma membrane upon stimulation at 4 C, where EGFR internalization, but not its activation, is blocked (Figure S7G) . The monoubiquitination-impaired mutant performed similar to wild-type Eps15 ( Figure S7G ). We then followed the localization of Eps15 at different time points after EGF stimulation ( Figures 7D and 7E) . Around 50%-60% of the internalized EGF colocalized with wild-type Eps15 at 10 and 20 min after stimulation ( Figure 7E ). In contrast with these results, the 6KR mutant showed a clear defect of colocalization with EGFR at the level of the endosomes ( Figure 7E) . Thus, the 6KR mutant, which is unable to rescue EGFR internalization defect, is also incompetent to co-traffic with the receptor. 
DISCUSSION
Long-term attenuation of EGFR signaling is achieved through internalization of the activated receptor and its degradation in lysosomes. In this context, ubiquitin plays a fundamental role because it acts, at various molecular levels, as a signal for the internalization and the intracellular sorting of the receptor [9, 10] . Because the down-modulation of the receptor is crucial for the maintenance of cellular homeostasis, many efforts have been directed at the identification and the elucidation of the molecular workings of the machinery executing the ubiquitination of EGFR and of the associated endocytic proteins [9, 10] . Comparatively less is presently known on the counteracting mechanisms that rely on deubiquitinating enzymes. In this study, we provide evidence that this latter process is vaster and more complex than previously thought, as at least 18 DUBs (of which only five were previously known) affect the degradation kinetics of EGFR. From this point of view, the impact of the deubiquitination machinery on EGFR physiology appears as complex as in the case of other receptor tyrosine kinases, such as Met (the HGF receptor), for which up to 12 DUBs have been identified that orchestrate multiple steps of the response to its activation [47] . This is not surprising because DUBs may affect EGFR fate either directly, acting at the various steps of the endocytic pathways, or indirectly, impinging on feedback regulatory loops active on the EGFR pathway [4] . Whereas, in our present study, we concentrated our efforts on the characterization of the role of USP9X in the modulation of EGFR fate, our findings might prompt future in-depth analyses of the impact several other DUBs have on the EGFR pathway.
USP9X Is a DUB for Eps15
We identified USP9X as a potent DUB required for the downmodulation of the EGFR pathway. USP9X depletion caused a defect in EGFR internalization, at both low and high doses of EGF, and delayed the kinetics of EGFR trafficking to the lysosomes. However, silencing of USP9X did not increase EGFR ubiquitination, arguing that the receptor itself is not the direct target. Conversely, we provide in vivo and in vitro evidence that the endocytic protein Eps15 is a USP9X substrate. An additional yet to be confirmed target may be epsin1/2. In D. melanogaster, Faf, the fly ortholog of human FAM/USP9X, physically associates with liquid facets, the fly ortholog of mammal epsin, preventing its proteasomal degradation [48] . In mammals, however, the result of the action of USP9X is unlikely to involve enhanced degradation of Eps15/epsin, as also witnessed by the finding that, under condition of USP9X depletion, the steady-state levels of these proteins were unaltered ( Figure 5B ). Indeed, Eps15 and epsin(s) are monoubiquitinated upon EGFR activation: a modification not linked to regulation of protein turnover but rather to the modulation of the protein:protein interaction ability determined by ubiquitin [49] .
The exact molecular mechanism through which USP9X modulates EGFR internalization remains to be established. Here, we present clear evidences that deubiquitination of Eps15 is part of the mechanism, as (1) inhibition of EGFR internalization, under conditions of USP9X depletion, correlates with increased ubiquitination of the endocytic proteins and not of the receptor itself; (2) monoubiquitination of Eps15 is required for EGFR internalization (see additional discussion further down) and yet USP9X-mediated deubiquitination events are required, as demonstrated by USP9X depletion; (3) molecular genetics evidence ( Figure 6A ) suggests that Eps15/epsin(s) and USP9X act in the same molecular pathway required for receptor internalization; and (4) monoubiquitination of Eps15 and USP9X activity are both required upon minimal activation of the EGFR (low EGF concentration). Thus, the sum of our results is highly compatible with the possibility that cycles of ubiquitination/ deubiquitination of endocytic adaptor proteins are required for EGFR internalization already at low EGF concentration, when only the clathrin pathway is operative [11] [12] [13] [14] . Indeed, dynamic ubiquitination and deubiquitination of the endocytic machinery has been recently postulated to regulate clathrin coat assembly and disassembly in yeast [50] .
A similar interpretative scenario might apply also to the second phenotype observed upon USP9X knockdown, i.e., the trafficking defect. Whereas this phenotype remains to be studied in detail, a simple idea is that, at the endosomal level, USP9X must deubiquitinate other endocytic adaptors to allow the EGFR to be trafficked to the lysosomes. Multiple ESCRT complexes mediate translocation of ubiquitinated EGFR into the internal vesicles of the MVB [9, 51] . Eps15b or Hrs would be possible substrates for USP9X at this later step, as they are known to act as ESCRT-0 complex [52] and to undergo monoubiquitination upon EGF stimulation [19] .
The Role of Endocytic Adaptor Monoubiquitination in EGFR Internalization
EGF-mediated monoubiquitination of endocytic proteins has been known for quite some time [19, 20, 22 ], yet we do not have a clear picture of its function. Our results highlight a crucial involvement of this post-translational modification in EGFR internalization.
Previous data have suggested that, once ubiquitinated, endocytic adaptor proteins are kept in a close conformation to prevent interaction with their cargos [23, 46] . In the case of EGFR internalization, however, the impact of ubiquitination on the function of Eps15 seems to involve a different mechanism. First, we could not demonstrate any change in the interaction of Eps15 with EGFR [14] or other partners ( Figures 7A-7C ) as a function of its monoubiquitination. Furthermore, by structure:function analysis, we showed that a monoubiquitination-incompetent mutant of Eps15, whereas capable of binding to EGFR (Figure S7F) , could not substitute for the wild-type protein in mediating EGFR internalization ( Figure 6D ) and does not co-traffic together with the EGFR (Figures 7D and 7E) . Thus, Eps15 monoubiquitination represents a positive requirement for the EGFR internalization process rather than a negative signal that disassembles the receptor-adaptor complex. Whether Eps15 monoubiquitination serves as a suitable protein:protein interaction platform remains to be further investigated. It is important to note that Eps15 monoubiquitination is not strictly EGF specific. Following Met activation, Eps15 is recruited to the plasma membrane and becomes both tyrosine-phosphorylated and ubiquitinated [53] . Further studies are needed to define whether Eps15 ubiquitination is also required for Met (or other RTKs) internalization.
EXPERIMENTAL PROCEDURES
Reagents, cell lines, qPCR, in vitro deubiquitination assay, 125 I-EGF and immunofluorescence-based internalization and trafficking assays, and mass spectrometry analysis are reported in the Supplemental Experimental Procedures.
DUB Library Screening
A list of 92 genes corresponding to DUBs in the human genome was compiled by manual curation of literature and protein databases. A DUB siRNA library consisting of a pool of two stealth oligos per DUB gene target was purchased from Invitrogen. Transfections were performed using RNAi Max (Invitrogen) and 10 nM RNAi pools. Cells were subjected to double transfection, ''reverse'' (cells in suspension) on day 1 and ''forward'' (adherent cells) on day 2. Cells were then processed 48-72 hr after the second transfection. After an overnight starvation, cells were stimulated with 100 ng/ml of EGF for 10, 60, 90, and 120 min at 37 C. Lysates were prepared in RIPA 1% SDS buffer and diluted to 0.2% SDS before incubation step. The screening was performed once. Replicates have been performed occasionally whenever technical issues arose.
ELISA-Based Assay, DELFIA For the ELISA-based assay, we used the DELFIA technology from Perkin Elmer. Microwell plates were coated with the capturing antibody (806; home-made polyclonal directed against aas 1,172-1,186 of human EGFR; 5 mg/ml). Blocking was performed for 2 hr with BSA 2% in PBS. Twenty-five micrograms of lysates from HeLa cells, stimulated with 100 ng/ml of EGF, were incubated overnight at 4 C for the ubiquitination detection or 1 hr at RT for total EGFR detection. After three washes, wells were incubated with primary antibodies (either the anti-Ub FK2 or the anti-EGFR monoclonal m108 diluted at 1 mg/ml in assay buffer) for 1 hr at RT. After three washes, anti-mouse or rabbit europium-labeled secondary antibodies (1 mg/ml in assay buffer) were added for an additional hour. After three washes and treatment with enhancement solution, fluorescence was measured with EnVision instrument (excitation at 340 nm and emission at 615 nm).
Biochemical Assays
Cell lysis was performed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor cocktail (CALBIOCHEM) and NEM (N-ethylmaleimide; 5 mM). The EGFR immunoblots were quantified using the ImageJ software. In all experiments, densitometry was performed on different exposures of the blots and results were obtained in the linear phase of the exposure. For each DUBs KD, results were expressed as ''fold variation over T0'' as they were normalized to the numerical value at time 0 (that may vary between the different cell lines).
Immunoprecipitations were performed in RIPA buffer. Three hundred micrograms of total cell lysate were used in the case of EGFR IP (anti-EGFR 806; 10 mg/mg); 500 mg of total cell lysate for Eps15 (anti-Eps15 SI0861 serum; 10 ml/mg) or epsin1/2 (anti-Epsin1/2 ZZ3; 15 ml/mg) and for HA IP (anti-HA beads; 20 ml/mg); and 1 mg of total lysate for Ub IP (anti-Ub FK2 beads; 10 ml/mg). For coIP experiments, lysis was performed in JS buffer (50 mM HEPES [pH 7.5], 50 mM NaCl, 1% glycerol, 1% Triton X-100, 1.5 mM MgCl, and 25 mM EGTA).
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